Glow Festival by Prudential 2025: A Cultural Reset for Whole-Person Wellness
With global stars, bold conversations, and Singapore's first 60KM national ultra marathon, the fourth edition marks a bold new chapter for Singapore's wellness movement SINGAPORE, May 21, 2025 /PRNewswire/ -- Glow Festival by Prudential 2025 returns from 5 to 13 July 2025, transforming Marina Bay Sands Event Plaza into Singapore's epicentre of modern wellbeing. In its fourth...
Elyon Family Clinic Launches STD Testing Packages Amid Rising Sexual Health Awareness
SINGAPORE, May 21, 2025 /PRNewswire/ -- Elyon Family Clinic & Surgery, an STD clinic in Singapore, has expanded its diagnostic offerings with the launch of two new testing packages: the STI-7 Multiplex Panel and the Genital Ulcer Assay. These additions are in line with the clinic's ongoing commitment to improving early detection and clinical outcomes in the area...
Accropeutics Announces Positive Data from Phase 2 Trial of AC-201, an oral, selective TYK2/JAK1 Inhibitor, for the treatment of Moderate-to-Severe Plaque Psoriasis
Phase 2 primary endpoint of PASI-75 and key secondary endpoints met in all of the three dosing groups at Week 12 AC-201 was generally well tolerated at all dose levels with no SAEs or AEs leading to discontinuation Efficacy and safety findings from this Phase 2 trial support advancing AC-201 into Phase 3 development for plaque psoriasis. ...
Lumenato™ Receives EFSA Approval, Expanding Market Availability
BRANCHBURG, N.J., May 21, 2025 /PRNewswire/ -- The European Food Safety Authority (EFSA) Panel on Nutrition, Novel Foods and Food Allergens has delivered a positive scientific opinion on Lumenato™, a standardized yellow tomato extract developed exclusively by Lycored, the global leader in natural carotenoids for food, beverage and dietary supplement products. The...
ESOC 2025: Combined oral contraceptives triple risk of cryptogenic stroke in young women, new study shows
HELSINKI, May 21, 2025 /PRNewswire/ -- New research presented today at the European Stroke Organisation Conference (ESOC) 2025 revealed that the use of combined oral contraceptives (OCs) is associated with a threefold increase in the risk of cryptogenic ischaemic stroke (CIS) in young women.(1) The findings add to a growing body of evidence linking hormonal contraception to vascular...
Health In Tech to Participate as Gold Sponsor at American Trust Investment Services National Conference 2025
STUART, Fl., May 21, 2025 /PRNewswire/ -- Health In Tech (Nasdaq: HIT), an Insurtech platform company backed by third-party AI technology, today announced that CEO Tim Johnson and CFO Julia Qian will represent the company as a Gold Sponsor at the American Trust Investment Services National Conference 2025, to be held June...
PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation (IFLI) Announce The First Follicular Lymphoma (FL) Patient Treated with BAFF-R Targeting CAR-T Cells (PMB-CT01) Achieves a Complete Response
The first heavily pretreated r/r FL patient dosed at City of Hope with PMB-CT01 achieved a CR at one-month post treatment. A Total of 7/7 r/r B-NHL patients including MCL, DLBCL and FL treated with PMB-CT01 have achieved a sustained CR (1 to 29+ months) with strictly grade 1 CRS and ICANS...
Race Walking Emerges as the Next Big Cardio Trend: Fast Walking for Optimal Fitness
MIAMI, May 20, 2025 /PRNewswire/ -- Regular walking is universally celebrated as a great way to keep moving, but often it doesn't elevate the heart rate sufficiently for serious cardiovascular benefits. Enter Race Walking—an Olympic Track & Field event since 1904—that combines intense cardio benefits of running without the joint-pounding impacts. "Race Walking provides all the health benefits...
Global Bakery Expo Spotlight: Angel Yeast Launches Feravor™ – A Revolutionary Natural Flavor Solution for Clean-Label Baking
SHANGHAI and DUSSELDORF, Germany, May 20, 2025 /PRNewswire/ -- At Europe's IBA 2025 and Asia's China Bakery Exhibition, Angel Yeast (SH600298) captured global attention with its groundbreaking Feravor™ series. This innovative flavored yeast solution, available in Floral-Fruity and Butter variants, empowers bakers to meet clean-label demands with natural, flavor-enhancing technology. ...
Registrational Phase III AMPLIFY trial in biochemical recurrence of prostate cancer commences
SYDNEY, May 20, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that it has commenced its second registrational Phase III 64Cu-SAR-bisPSMA diagnostic trial in prostate cancer, AMPLIFY (NCT06970847)1,...
